Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 215

1.

Multiple Sclerosis Performance Test: Technical Development and Usability.

Rhodes JK, Schindler D, Rao SM, Venegas F, Bruzik ET, Gabel W, Williams JR, Phillips GA, Mullen CC, Freiburger JL, Mourany L, Reece C, Miller DM, Bethoux F, Bermel RA, Krupp LB, Mowry EM, Alberts J, Rudick RA.

Adv Ther. 2019 May 3. doi: 10.1007/s12325-019-00958-x. [Epub ahead of print]

PMID:
31054035
2.

Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis.

Strober L, DeLuca J, Benedict RH, Jacobs A, Cohen JA, Chiaravalloti N, Hudson LD, Rudick RA, LaRocca NG; Multiple Sclerosis Outcome Assessments Consortium (MSOAC).

Mult Scler. 2018 Oct 18:1352458518808204. doi: 10.1177/1352458518808204. [Epub ahead of print]

PMID:
30334474
3.

Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis: a retrospective study.

Trapp BD, Vignos M, Dudman J, Chang A, Fisher E, Staugaitis SM, Battapady H, Mork S, Ontaneda D, Jones SE, Fox RJ, Chen J, Nakamura K, Rudick RA.

Lancet Neurol. 2018 Oct;17(10):870-884. doi: 10.1016/S1474-4422(18)30245-X. Epub 2018 Aug 22.

PMID:
30143361
4.

Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis: A retrospective analysis.

Fisher E, Nakamura K, Lee JC, You X, Sperling B, Rudick RA.

Mult Scler. 2016 Apr;22(5):668-76. doi: 10.1177/1352458515599072. Epub 2015 Aug 3.

PMID:
26238463
5.

The Future of Research in Multiple Sclerosis.

Fox RJ, Rudick RA.

JAMA Neurol. 2015 Aug;72(8):853-4. doi: 10.1001/jamaneurol.2015.0270. No abstract available.

PMID:
26053218
6.

Experience with fingolimod in clinical practice.

Hersh CM, Hara-Cleaver C, Rudick RA, Cohen JA, Bermel RA, Ontaneda D.

Int J Neurosci. 2015;125(9):678-85. doi: 10.3109/00207454.2014.969839. Epub 2014 Oct 29.

7.

The clinical meaning of walking speed as measured by the timed 25-foot walk in patients with multiple sclerosis.

Cohen JA, Krishnan AV, Goodman AD, Potts J, Wang P, Havrdova E, Polman C, Rudick RA.

JAMA Neurol. 2014 Nov;71(11):1386-93. doi: 10.1001/jamaneurol.2014.1895.

PMID:
25178496
8.

Factors associated with clinically significant increased walking time in multiple sclerosis: results of a survival analysis of short-term follow-up data from a clinical database.

Miller DM, Thompson NR, Cohen JA, Fox RJ, Hartman J, Schwetz K, Conway DS, Rudick RA.

Mult Scler. 2015 Apr;21(4):457-65. doi: 10.1177/1352458514544536. Epub 2014 Aug 11.

PMID:
25112816
9.

The Multiple Sclerosis Performance Test (MSPT): an iPad-based disability assessment tool.

Rudick RA, Miller D, Bethoux F, Rao SM, Lee JC, Stough D, Reece C, Schindler D, Mamone B, Alberts J.

J Vis Exp. 2014 Jun 30;(88):e51318. doi: 10.3791/51318.

10.

Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study.

O'Connor P, Goodman A, Kappos L, Lublin F, Polman C, Rudick RA, Hauswirth K, Cristiano LM, Forrestal F, Duda P.

Neurology. 2014 Jul 1;83(1):78-86. doi: 10.1212/WNL.0000000000000541. Epub 2014 Jun 4. Erratum in: Neurology. 2014 Aug 19;83(8):773.

11.

Defining the clinical course of multiple sclerosis: the 2013 revisions.

Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B Jr, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH.

Neurology. 2014 Jul 15;83(3):278-86. doi: 10.1212/WNL.0000000000000560. Epub 2014 May 28.

12.

Simple MRI metrics contribute to optimal care of the patient with multiple sclerosis.

Simon JH, Bermel RA, Rudick RA.

AJNR Am J Neuroradiol. 2014 May;35(5):831-2. doi: 10.3174/ajnr.A3937. Epub 2014 Apr 3. No abstract available.

13.

Assessing treatment response to interferon-β: is there a role for MRI?

Dobson R, Rudick RA, Turner B, Schmierer K, Giovannoni G.

Neurology. 2014 Jan 21;82(3):248-54. doi: 10.1212/WNL.0000000000000036. Epub 2013 Dec 11. Review.

14.

Multiple Sclerosis Outcome Assessments Consortium: Genesis and initial project plan.

Rudick RA, Larocca N, Hudson LD; MSOAC.

Mult Scler. 2014 Jan;20(1):12-7. doi: 10.1177/1352458513503392. Epub 2013 Sep 20. Review.

PMID:
24057430
15.

Preventing brain atrophy should be the gold standard of effective therapy in MS (after the first year of treatment): Yes.

Rudick RA, Fisher E.

Mult Scler. 2013 Jul;19(8):1003-4. doi: 10.1177/1352458513482385. No abstract available.

PMID:
23818018
16.

MRI lesions: a surrogate for relapses in multiple sclerosis?

Rudick RA, Cutter G.

Lancet Neurol. 2013 Jul;12(7):628-30. doi: 10.1016/S1474-4422(13)70108-X. Epub 2013 Jun 3. No abstract available.

PMID:
23743083
17.

Reliability of classifying multiple sclerosis disease activity using magnetic resonance imaging in a multiple sclerosis clinic.

Erbayat Altay E, Fisher E, Jones SE, Hara-Cleaver C, Lee JC, Rudick RA.

JAMA Neurol. 2013 Mar 1;70(3):338-44.

18.

Author response to comment on "time to integrate clinical and research informatics".

Katzan IL, Rudick RA.

Sci Transl Med. 2013 Apr 3;5(179):179lr1. doi: 10.1126/scitranslmed.3006031.

19.

Author response.

Rudick RA, Miller A.

Neurology. 2013 Feb 19;80(8):777. No abstract available.

PMID:
23544194
20.

Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.

Bermel RA, You X, Foulds P, Hyde R, Simon JH, Fisher E, Rudick RA.

Ann Neurol. 2013 Jan;73(1):95-103. doi: 10.1002/ana.23758.

PMID:
23378325
21.

Time to integrate clinical and research informatics.

Katzan IL, Rudick RA.

Sci Transl Med. 2012 Nov 28;4(162):162fs41. doi: 10.1126/scitranslmed.3004583.

PMID:
23197569
22.

Measurement and clinical effect of grey matter pathology in multiple sclerosis.

Geurts JJ, Calabrese M, Fisher E, Rudick RA.

Lancet Neurol. 2012 Dec;11(12):1082-92. doi: 10.1016/S1474-4422(12)70230-2. Review.

PMID:
23153407
23.

Early tolerability and safety of fingolimod in clinical practice.

Ontaneda D, Hara-Cleaver C, Rudick RA, Cohen JA, Bermel RA.

J Neurol Sci. 2012 Dec 15;323(1-2):167-72. doi: 10.1016/j.jns.2012.09.009. Epub 2012 Oct 3.

24.

Revisiting the multiple sclerosis functional composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures.

Ontaneda D, LaRocca N, Coetzee T, Rudick R; NMSS MSFC Task Force.

Mult Scler. 2012 Aug;18(8):1074-80. doi: 10.1177/1352458512451512. Epub 2012 Jun 27.

PMID:
22740488
25.

Multiple sclerosis or multiple possibilities: the continuing problem of misdiagnosis.

Rudick RA, Miller AE.

Neurology. 2012 Jun 12;78(24):1904-6. doi: 10.1212/WNL.0b013e318259e2e2. Epub 2012 May 11. No abstract available.

PMID:
22581931
26.

The elusive biomarker for personalized medicine in multiple sclerosis: the search continues.

Rudick RA.

Neurology. 2012 Aug 7;79(6):498-9. doi: 10.1212/WNL.0b013e318259e13a. Epub 2012 May 9. No abstract available.

PMID:
22573625
27.

MS clinical trials: what can subgroup analyses teach us?

Rudick RA.

Lancet Neurol. 2012 May;11(5):386-8. doi: 10.1016/S1474-4422(12)70066-2. Epub 2012 Apr 10. No abstract available.

PMID:
22494954
28.

Risk stratification and patient counseling for natalizumab in multiple sclerosis.

Fox RJ, Rudick RA.

Neurology. 2012 Feb 7;78(6):436-7. doi: 10.1212/WNL.0b013e318245d2d0. Epub 2012 Jan 25. No abstract available.

PMID:
22282644
29.

Multiple sclerosis, natalizumab, and PML: helping patients decide.

Rudick RA.

Cleve Clin J Med. 2011 Nov;78 Suppl 2:S18-23. doi: 10.3949/ccjm.78.s2.05.

PMID:
22123928
30.

The role of cell type-specific responses in IFN-β therapy of multiple sclerosis.

Zula JA, Green HC, Ransohoff RM, Rudick RA, Stark GR, van Boxel-Dezaire AH.

Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):19689-94. doi: 10.1073/pnas.1117347108. Epub 2011 Nov 21.

31.

Oral treatment for multiple sclerosis.

Killestein J, Rudick RA, Polman CH.

Lancet Neurol. 2011 Nov;10(11):1026-34. doi: 10.1016/S1474-4422(11)70228-9. Review.

PMID:
22014437
32.

Excessive biologic response to IFNβ is associated with poor treatment response in patients with multiple sclerosis.

Rudick RA, Rani MR, Xu Y, Lee JC, Na J, Shrock J, Josyula A, Fisher E, Ransohoff RM.

PLoS One. 2011;6(5):e19262. doi: 10.1371/journal.pone.0019262. Epub 2011 May 13.

33.

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis.

O'Connor PW, Goodman A, Kappos L, Lublin FD, Miller DH, Polman C, Rudick RA, Aschenbach W, Lucas N.

Neurology. 2011 May 31;76(22):1858-65. doi: 10.1212/WNL.0b013e31821e7c8a. Epub 2011 May 4.

PMID:
21543733
34.

Challenges to clinical trials in multiple sclerosis: outcome measures in the era of disease-modifying drugs.

Hyland M, Rudick RA.

Curr Opin Neurol. 2011 Jun;24(3):255-61. doi: 10.1097/WCO.0b013e3283460542. Review.

PMID:
21455068
35.

Beta-interferon for multiple sclerosis.

Rudick RA, Goelz SE.

Exp Cell Res. 2011 May 15;317(9):1301-11. doi: 10.1016/j.yexcr.2011.03.002. Epub 2011 Mar 21. Review.

PMID:
21396360
36.

Diagnostic criteria in multiple sclerosis: headed in the right direction but still a ways to go.

Rudick RA.

Ann Neurol. 2011 Feb;69(2):234-6. doi: 10.1002/ana.22388. No abstract available.

PMID:
21387367
37.

Change in quality of life in patients with relapsing-remitting multiple sclerosis over 2 years in relation to other clinical parameters: results from a trial of intramuscular interferon {beta}-1a.

Miller DM, Weinstock-Guttman B, Bourdette D, You X, Foulds P, Rudick RA.

Mult Scler. 2011 Jun;17(6):734-42. doi: 10.1177/1352458510397221. Epub 2011 Feb 7.

PMID:
21300736
38.

Web-based self-management for patients with multiple sclerosis: a practical, randomized trial.

Miller DM, Moore SM, Fox RJ, Atreja A, Fu AZ, Lee JC, Saupe W, Stadtler M, Chakraborty S, Harris CM, Rudick RA.

Telemed J E Health. 2011 Jan-Feb;17(1):5-13. doi: 10.1089/tmj.2010.0133. Epub 2011 Jan 9.

39.

Possible clinical outcome measures for clinical trials in patients with multiple sclerosis.

Goldman MD, Motl RW, Rudick RA.

Ther Adv Neurol Disord. 2010 Jul;3(4):229-39. doi: 10.1177/1756285610374117.

40.

Gender effects on intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis: analysis of 1406 patients.

Rudick RA, Kappos L, Kinkel R, Clanet M, Phillips JT, Herndon RM, Sandrock AW, Munschauer FE 3rd.

Mult Scler. 2011 Mar;17(3):353-60. doi: 10.1177/1352458510384605. Epub 2010 Oct 21.

PMID:
20965959
41.

Multiple sclerosis: is multiple sclerosis caused by venous insufficiency?

Rudick RA.

Nat Rev Neurol. 2010 Sep;6(9):472-4. doi: 10.1038/nrneurol.2010.117. No abstract available.

PMID:
20811464
42.

Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks.

Morrow SA, O'Connor PW, Polman CH, Goodman AD, Kappos L, Lublin FD, Rudick RA, Jurgensen S, Paes D, Forrestal F, Benedict RH.

Mult Scler. 2010 Nov;16(11):1385-92. doi: 10.1177/1352458510378021. Epub 2010 Aug 25.

PMID:
20739335
43.

Assessment of JC virus DNA in blood and urine from natalizumab-treated patients.

Rudick RA, O'Connor PW, Polman CH, Goodman AD, Ray SS, Griffith NM, Jurgensen SA, Gorelik L, Forrestal F, Sandrock AW, Goelz SE.

Ann Neurol. 2010 Sep;68(3):304-10. doi: 10.1002/ana.22107.

PMID:
20737514
44.

Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: eight-year follow-up.

Rudick RA, Lee JC, Cutter GR, Miller DM, Bourdette D, Weinstock-Guttman B, Hyde R, Zhang H, You X.

Arch Neurol. 2010 Nov;67(11):1329-35. doi: 10.1001/archneurol.2010.150. Epub 2010 Jul 12.

PMID:
20625068
45.

Measuring disability in relapsing-remitting MS.

Rudick RA, Kappos L.

Neurology. 2010 Jul 27;75(4):296-7. doi: 10.1212/WNL.0b013e3181ecf815. Epub 2010 Jun 30. No abstract available.

PMID:
20592252
46.

Validation of a self-report comorbidity questionnaire for multiple sclerosis.

Horton M, Rudick RA, Hara-Cleaver C, Marrie RA.

Neuroepidemiology. 2010 Aug;35(2):83-90. doi: 10.1159/000311013. Epub 2010 Jun 15.

47.

The multiple sclerosis functional composite: a clinically meaningful measure of disability.

Polman CH, Rudick RA.

Neurology. 2010 Apr 27;74 Suppl 3:S8-15. doi: 10.1212/WNL.0b013e3181dbb571. Review.

PMID:
20421572
48.

Patient-centered outcomes: translating clinical efficacy into benefits on health-related quality of life.

Miller D, Rudick RA, Hutchinson M.

Neurology. 2010 Apr 27;74 Suppl 3:S24-35. doi: 10.1212/WNL.0b013e3181dbb884.

PMID:
20421570
49.

A radical proposal: integrate clinical investigation into the U.S. health care system.

Rudick RA, Cosgrove DM.

Sci Transl Med. 2009 Oct 28;1(4):4cm4. doi: 10.1126/scitranslmed.3000296.

PMID:
20368168
50.

Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.

Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators.

J Neurol Sci. 2010 May 15;292(1-2):28-35. doi: 10.1016/j.jns.2010.02.012. Epub 2010 Mar 16.

PMID:
20236661

Supplemental Content

Loading ...
Support Center